The Filing Desk

Neogen vs RxSight

Neogen NEOG · RxSight RXST · Health Care Supplies

Neogen reported revenue of $870 million in fiscal 2026, 6.5 times RxSight's $134 million in fiscal 2025. Neogen's revenue fell 2.7% in its latest year, and RxSight's fell 3.9%. Neogen had an operating margin of -2.5%, against -35.8% at RxSight. Free cash flow was $32 million at Neogen and −$19 million at RxSight. Their fiscal years end in different months (May 31 and December 31), so the periods don't line up exactly.

Side by side

NeogenRxSight
Latest fiscal yearFY2026, May 31, 2026FY2025, Dec 31, 2025
Revenue$870M$134M
Revenue growth−2.7%−3.9%
Revenue growth a year, last 5 years13.2%55.7%
Gross margin46.9%76.6%
Operating margin−2.5%−35.8%
Net margin−0.9%−29.0%
Free cash flow$32M−$19M
Free cash flow margin3.7%−14.4%
Return on capital−0.6%−82.9%
Net debt to EBITDA6.4x—
Dividends and buybacks$0M$0M
Change in diluted share count0.3%5.1%
Last close$10.85$4.61
P/E at the last close——
Insider trades, last 12 monthsbought $6,386, sold $114,676sold $103,745
Piotroski F-score5 of 93 of 9
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
NeogenRxSight
Operating margin
Percent of revenue
NeogenRxSight
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
NeogenRxSight

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Neogen and RxSight pages.